In the latest powerpoint presentation on what is in/out of scope for the CCDD, investigational agents are considered as out of scope. I agree that agents tested in phase 1 clinical trials for now can be considered out of scope. At a certain stage an investigational agent might already have a DIN assigned. If so do we still want this agent to be "out of scope" ?
Imprimer
Courriel
CCDD and scope for Investigational Agents (Medications)
Twitter